The identification of actionable target mutations, such as CSF3R, Jak2, RAS, and MEK mutations, open the way to a new era in treatment of aCML patients. The gene discussed is MAP2K7; the disease is atypical chronic myeloid leukemia, BCR-ABL1 negative.